These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
215 related articles for article (PubMed ID: 37076338)
1. Toward Precision Medicine: Development and Validation of A Machine Learning Based Decision Support System for Optimal Sequencing in Castration-Resistant Prostate Cancer. Lim H; Yoo JW; Lee KS; Lee YH; Baek S; Lee S; Kang H; Choi YD; Ham WS; Lee SH; Chung BH; Halawani A; Ahn JH; Koo KC Clin Genitourin Cancer; 2023 Aug; 21(4):e211-e218.e4. PubMed ID: 37076338 [TBL] [Abstract][Full Text] [Related]
2. Long short-term memory artificial neural network model for prediction of prostate cancer survival outcomes according to initial treatment strategy: development of an online decision-making support system. Koo KC; Lee KS; Kim S; Min C; Min GR; Lee YH; Han WK; Rha KH; Hong SJ; Yang SC; Chung BH World J Urol; 2020 Oct; 38(10):2469-2476. PubMed ID: 31925552 [TBL] [Abstract][Full Text] [Related]
3. Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agents. Pezaro CJ; Omlin AG; Altavilla A; Lorente D; Ferraldeschi R; Bianchini D; Dearnaley D; Parker C; de Bono JS; Attard G Eur Urol; 2014 Sep; 66(3):459-65. PubMed ID: 24411987 [TBL] [Abstract][Full Text] [Related]
4. Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study. Caffo O; De Giorgi U; Fratino L; Alesini D; Zagonel V; Facchini G; Gasparro D; Ortega C; Tucci M; Verderame F; Campadelli E; Lo Re G; Procopio G; Sabbatini R; Donini M; Morelli F; Sartori D; Zucali P; Carrozza F; D'Angelo A; Vicario G; Massari F; Santini D; Sava T; Messina C; Fornarini G; La Torre L; Ricotta R; Aieta M; Mucciarini C; Zustovich F; Macrini S; Burgio SL; Santarossa S; D'Aniello C; Basso U; Tarasconi S; Cortesi E; Buttigliero C; Ruatta F; Veccia A; Conteduca V; Maines F; Galligioni E Eur Urol; 2015 Jul; 68(1):147-53. PubMed ID: 25457020 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Cabazitaxel Versus Abiraterone or Enzalutamide in Older Patients with Metastatic Castration-resistant Prostate Cancer in the CARD Study. Sternberg CN; Castellano D; de Bono J; Fizazi K; Tombal B; Wülfing C; Kramer G; Eymard JC; Bamias A; Carles J; Iacovelli R; Melichar B; Sverrisdóttir Á; Theodore C; Feyerabend S; Helissey C; Poole EM; Ozatilgan A; Geffriaud-Ricouard C; de Wit R Eur Urol; 2021 Oct; 80(4):497-506. PubMed ID: 34274136 [TBL] [Abstract][Full Text] [Related]
6. Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone. Bianchini D; Lorente D; Rodriguez-Vida A; Omlin A; Pezaro C; Ferraldeschi R; Zivi A; Attard G; Chowdhury S; de Bono JS Eur J Cancer; 2014 Jan; 50(1):78-84. PubMed ID: 24074764 [TBL] [Abstract][Full Text] [Related]
7. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N; Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502 [TBL] [Abstract][Full Text] [Related]
8. Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer. Antonarakis ES; Lu C; Luber B; Wang H; Chen Y; Nakazawa M; Nadal R; Paller CJ; Denmeade SR; Carducci MA; Eisenberger MA; Luo J JAMA Oncol; 2015 Aug; 1(5):582-91. PubMed ID: 26181238 [TBL] [Abstract][Full Text] [Related]
10. Oncologic Response and Hospitalization Rate of Patients Receiving Cabazitaxel in the Fourth-Line and Beyond in Castration-Resistant Prostate Cancer: Analysis of a Retrospective Cohort and a Structured Literature Review. von Hardenberg J; Schwartz M; Werner T; Fuxius S; Strauss A; Worst TS; Nuhn P; Bolenz C; Heinrich E Urol Int; 2017; 99(4):414-421. PubMed ID: 28700990 [TBL] [Abstract][Full Text] [Related]
11. Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial. Beer TM; Hotte SJ; Saad F; Alekseev B; Matveev V; Fléchon A; Gravis G; Joly F; Chi KN; Malik Z; Blumenstein B; Stewart PS; Jacobs CA; Fizazi K Lancet Oncol; 2017 Nov; 18(11):1532-1542. PubMed ID: 29033099 [TBL] [Abstract][Full Text] [Related]
12. Sequencing of Taxanes and New Androgen-targeted Therapies in Metastatic Castration-resistant Prostate Cancer: Results of the International Multicentre Retrospective CATS Database. Delanoy N; Hardy-Bessard AC; Efstathiou E; Le Moulec S; Basso U; Birtle A; Thomson A; Krainer M; Guillot A; De Giorgi U; Hasbini A; Daugaard G; Bahl A; Chowdhury S; Caffo O; Beuzeboc P; Spaeth D; Eymard JC; Fléchon A; Alexandre J; Helissey C; Butt M; Priou F; Lechevallier É; Deville JL; Goupil MG; Morales R; Thiery-Vuillemin A; Gavrikova T; Barthelemy P; Sella A; Fizazi K; Baciarello G; Fererro JM; Laguerre B; Verret B; Hans S; Oudard S Eur Urol Oncol; 2018 Dec; 1(6):467-475. PubMed ID: 31158090 [TBL] [Abstract][Full Text] [Related]
13. Bone targeted therapy and skeletal related events in the era of enzalutamide and abiraterone acetate for castration resistant prostate cancer with bone metastases. McGregor B; Zhang L; Gray KP; Shaw G; Evan C; Francini E; Sweeney C Prostate Cancer Prostatic Dis; 2021 Jun; 24(2):341-348. PubMed ID: 32884090 [TBL] [Abstract][Full Text] [Related]
14. HSD3B1 (1245A>C) germline variant and clinical outcomes in metastatic castration-resistant prostate cancer patients treated with abiraterone and enzalutamide: results from two prospective studies. Khalaf DJ; Aragón IM; Annala M; Lozano R; Taavitsainen S; Lorente D; Finch DL; Romero-Laorden N; Vergidis J; Cendón Y; Oja C; Pacheco MI; Zulfiqar M; ; Gleave ME; Wyatt AW; Olmos D; Chi KN; Castro E Ann Oncol; 2020 Sep; 31(9):1186-1197. PubMed ID: 32574722 [TBL] [Abstract][Full Text] [Related]
15. The Effect of Treatment Sequence on Overall Survival for Men With Metastatic Castration-resistant Prostate Cancer: A Multicenter Retrospective Study. Okita K; Hatakeyama S; Narita S; Takahashi M; Sakurai T; Kawamura S; Hoshi S; Ishida M; Kawaguchi T; Ishidoya S; Shimoda J; Sato H; Mitsuzuka K; Ito A; Tsuchiya N; Arai Y; Habuchi T; Ohyama C Clin Genitourin Cancer; 2020 Apr; 18(2):e103-e111. PubMed ID: 31810867 [TBL] [Abstract][Full Text] [Related]
16. Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies. Crawford ED; Higano CS; Shore ND; Hussain M; Petrylak DP J Urol; 2015 Dec; 194(6):1537-47. PubMed ID: 26196735 [TBL] [Abstract][Full Text] [Related]
17. Enzalutamide treatment in patients with metastatic castration-resistant prostate cancer progressing after chemotherapy and abiraterone acetate. Thomsen FB; Røder MA; Rathenborg P; Brasso K; Borre M; Iversen P Scand J Urol; 2014 Jun; 48(3):268-75. PubMed ID: 24255983 [TBL] [Abstract][Full Text] [Related]